- Company
- Q3 exports of Biopharmas 'Good’ Diagnostic kits ‘Slow'
- by Kim, Jin-Gu Oct 21, 2021 05:13am
- While pharmaceutical exports in Q3 increased slightly compared to the same period of the previous year, the performance of biopharmaceuticals and chemical drugs have shown mixed results. Export of biopharmaceuticals increased 13% YOY and continued on its strong flow from last year, however, export of chemical drugs fell 13%. Also, diagnost
- Company
- Pfizer applies for reimbursement of 3rd-gen ALKi Lorviqua
- by Eo, Yun-Ho Oct 20, 2021 05:56am
- Pfizer is aiming to introduce a second ALK inhibitor after ‘Xalkori’ into Korea’s prescription market. According to industry sources, Pfizer Korea has recently submitted a reimbursement listing application for its anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), ‘Lorviqua (lorlatinib),’ which is in progress. Pfiz
- Company
- Moderna Korea speeds up group organization
- by Oct 20, 2021 05:56am
- Moderna Korea, which had shown little activity for almost 6 months after establishing its Korean subsidiary, is busy recruiting members in secrecy. With the active hiring and imminent production of Moderna vaccines, officials predict that the company will be starting its official activity soon. According to industry sources on the 19th,
- Company
- Hugel’s Geodu BTX plant completes EMA inspection
- by Lee, Seok-Jun Oct 19, 2021 06:00am
- [Hugel announced that the European Medicines Agency completed the on-site inspection of its ‘Geodu plant’ in Chuncheon on the 18th. The Geodu plant has a fully automated state-of-the-art system that can manufacture over five million botulinum toxin vials a year. EMA conducted an on-site inspection on the Geodu plant’s manufacturing
- Company
- Hugel's Letybo benefits from FDA delay of Revance's DAXI
- by Nho, Byung Chul Oct 18, 2021 05:54am
- The U.S. Food and Drug Administration’s disclosure of the official document outlining concerns in the DAXI manufacturing plant of the botulinum toxin company, Revance Therapeutics (hereinafter ‘Revance’), raised industry concerns about the uncertainty of the company’s approval. Revance is a new medical aesthetics company that sells
- Company
- Novartis applies for another gene therapy, Luxturna
- by Eo, Yun-Ho Oct 18, 2021 05:54am
- Novartis has applied for the registration of insurance benefits for another new one-shot gene therapy drug. According to related industries, Novartis Korea recently submitted an application for benefits for the Inherited Retinal Dystrophy (IRD) treatment "Luxturna (Voregenene Neparvovec). Luxturna restores its function by replacing the
- Company
- Bayer·Viatris·Pfizer settles in new locations
- by Eo, Yun-Ho Oct 18, 2021 05:54am
- News of multinational pharmaceutical companies’ relocations continue. According to industry sources, Korean subsidiaries of multinational pharmaceutical companies including Bayer, Viatris, and Pfizer have decided on their new offices and are working on relocation projects. Bayer Korea, which had been located in Boramae, Dongjak-Ku for
- Company
- Rediscovery of Clopidogrel brings back generic boom
- by Kim, Jin-Gu Oct 15, 2021 05:57am
- Development of generics using ‘clopidogrel,’ an antiplatelet drug, is regaining momentum. A company that already owned a clopidogrel generic has released a new dose product in 16 years. And the generic companies have been showing positive responses after the effect of clopidogrel was reilluminated in a study on stent-inserted patients,
- Company
- ‘Ibrance’ opens new horizon as the lead CDK4/6 inhibitor
- by Oct 14, 2021 05:38am
- The breast cancer treatment ‘Ibrance (palbociclib)’ was what established Pfizer Korea as the ‘anticancer drug power’ in Korea. The company had other excellent anticancer drugs such as ‘Xalkori,’ and ‘Sutene,’ but none had received as much spotlight as Ibrance. As the ‘first CDK4/6 inhibitor,’ and ‘the first new breast cancer drug i
- Company
- Korea Otsuka Pharma’s Hyangnam Plant rises as a global hub
- by Nho, Byung Chul Oct 14, 2021 05:38am
- Korea Otsuka Pharmaceutical, which is soon to face its 40th anniversary in Korea, is receiving attention with its Hyangnam Plant rising as a forward base for global exports and production. Korea Otsuka Pharmaceutical is a global total healthcare enterprise that covers a wide range of businesses from clinical research, R&D, manufacturing,
